MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: GTCbio - Biopharmaceutical Conference
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Gyorgi Keri of Vichem Chemie Research to Speak at Protein Kinases Mtg on May 8-9, 2014 in Berlin, Germany - Gyorgi Keri, Professor, CEO & CSO at Vichem Chemie Research Ltd will give a presentation titled “Developing Kinase Inhibitors for Personalized Therapy,” at the Protein Kinases in Drug Discovery Conference Europe in Berlin, Germany on May 8-9, 2014 by GTC
Gyorgi Keri of Vichem Chemie Research to Speak at Protein Kinases Mtg on May 8-9, 2014 in Berlin, Germany

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2013/12/15 - Gyorgi Keri, Professor, CEO & CSO at Vichem Chemie Research Ltd will give a presentation titled “Developing Kinase Inhibitors for Personalized Therapy,” at the Protein Kinases in Drug Discovery Conference Europe in Berlin, Germany on May 8-9, 2014 by GTC.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Gyorgi Keri is the founder of Vichem Chemie Res. Ltd and is a Professor at Semmelweis University. He got his PhD from biochemistry in Budapest, and was post doc. at University of California, San Francisco.

He has been working together with Professor Axel Ullrich (Max Planck Institute) for more than 25 years on developing kinase inhibitors. He was advisor and collaborative partner of SUgen Inc. from 1992 to 1999 and Axxima Pharmaceuticals from 1999 to 2005.

He has been involved in the development of several kinase inhibitors which have been licensed for external partners. He also developed the Nested Chemical Library™ (NCL) technology, based on a knowledge based approach where focused libraries of kinase inhibitors around more than 600 scaffolds are used for hit finding and to generate pharmacophore models.

Using the NCL™ kinase inhibitor library, Vichem has developed, and will further develop, kinase inhibitors which kill more than 95% of certain cancer cells (including cancer stem cells). The goal is to provide a personalized therapy and molecular diagnostic protocol to select who will respond to a particular cancer stem cell killing drug.

The Protein Kinases in Drug Discovery Conference Europe, to be held on May 8-9, 2014, in Berlin, Germany, will be a premier conference that will host an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus on drug discovery aspects within the protein kinases field. A balance of both academic and industry experts will facilitate discussion on validation of novel drug targets, current progress in drug design, kinases inhibitor development, and preclinical models and clinical development.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Gyorgi Keri of Vichem Chemie Research to Speak at Protein Kinases Mtg on May 8-9, 2014 in Berlin, Germany

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research
Global Bio-Based Chemicals Market Projected to Grow At a CAGR of 16.67% by 2027 Finds Inkwood Research
The Global Animal Nutrition Market Projected to Grow At a CAGR of 5.94% by 2027 Finds Inkwood Research
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-small Cell Lung Cancer
BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology
Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu
Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)